ORIC Pharmaceuticals will present combination dose optimization data from its Phase 1b trial of rinzimetostat, a drug for metastatic castration resistant prostate cancer (mCRPC), during a conference call on March 31, 2026. This data is important as it informs the effective dosing strategy for this promising cancer treatment. Investors and interested parties can join the live webcast or access the replay on the company's website. The update follows ORIC's focus on developing therapies that overcome cancer treatment resistance.
The global reactive hot melt adhesives market is projected to grow from $2.02 billion in 2025 to $4.29 billion by 2035, at a CAGR of 7.72%. Growth is driven by regulations limiting solvent-based adhesives, increased use of polyurethane adhesives in a...
Wendy's is running a $1 promotion on small Classic Chocolate or Vanilla Frosty from July 20 to August 23, with early access for Wendy's Rewards members on July 19 in celebration of National Ice Cream Day. The offer is redeemable via the Wendy's app a...
Dyadic International has expanded its bio-industrial pipeline with a new proprietary enzyme program focused on advanced cellulose processing, building on the success of its EN3ZYME™ product. This initiative leverages Dyadic's Dapibus™ platform to str...
Forum Markets has acquired a commercial aircraft engine for about $12 million, increasing its aviation portfolio to four engines leased to major U.S. airlines. The engine, a widely used CFM56-7B model, is already generating revenue under a long-term ...
Aduro Clean Technologies and ECOCE have completed Phase 1 of their collaboration to map flexible and multilayer plastic waste streams in Mexico, estimated at 1.5 million tonnes annually. Selected post-consumer flexible plastic packaging streams will ...
